Compare Lowe`s Companies Inc (LOW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Viatris Inc — how do they compare? Lowe`s Companies Inc trades at $202.53 (market cap $114.78B), while Viatris Inc trades at $17.3 (market cap $19.79B). The key difference: Lowe`s Companies Inc is far larger — about 5.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| LOW | VTRS | |
|---|---|---|
Market Cap | $114.78B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $17.39 |
52-Week Low | $204.76 | $8.74 |
Enterprise Value | $156.54B | $32.00B |
Dividend Yield | 2.44% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $204.08, down 2.23% on the day, amid a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.03 exceeding the $2.97 estimate. Revenue for 2025 was $83.67 billion, with a net income margin of 7.51%. The company maintains a strong dividend history, recently declaring a $1.25 per share dividend payable in August 2026.
The outlook is mixed. Strong analyst consensus, with a $260.88 price target and 60.79% buy ratings, suggests upside potential. However, high debt levels, with a debt-to-asset ratio of 82.33% for 2025, and a projected net cash flow deficit of $2.3 billion for 2026 present significant financial risks. Competitive pressures in the home improvement sector remain a key challenge.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
